KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Treasury Shares (2016 - 2025)

Moderna (MRNA) has disclosed Treasury Shares for 10 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 42.49% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $11.2 million, up 42.49%, while the annual FY2025 figure was $11.2 million, 42.49% up from the prior year.
  • Treasury Shares hit $11.2 million in Q4 2025 for Moderna, up from $7.9 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $23.0 million in Q4 2022 and bottomed at $2.2 million in Q3 2021.
  • Average Treasury Shares over 5 years is $8.4 million, with a median of $7.9 million recorded in 2023.
  • Year-over-year, Treasury Shares skyrocketed 792.86% in 2022 and then plummeted 65.22% in 2023.
  • Moderna's Treasury Shares stood at $3.0 million in 2021, then skyrocketed by 666.67% to $23.0 million in 2022, then tumbled by 65.22% to $8.0 million in 2023, then fell by 1.75% to $7.9 million in 2024, then skyrocketed by 42.49% to $11.2 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $11.2 million, $7.9 million, and $8.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.